TSC BioVenture Capital Corporation
3
24M
3
2
- Areas of investment
Summary
The fund was located in Asia if to be more exact in Taiwan. The main department of described VC is located in the Taipei.
The usual cause for the fund is to invest in rounds with 8 partakers. Despite the TSC BioVenture Capital Corporation, startups are often financed by Sycamore Ventures. The meaningful sponsors for the fund in investment in the same round are MDS Capital, United Investments, TVM Capital. In the next rounds fund is usually obtained by Sycamore Ventures, Lumira Ventures, iD Ventures America.
Deals in the range of 10 - 50 millions dollars are the general things for fund. The top activity for fund was in 2006. The fund is constantly included in less than 2 deals per year.
For fund there is no match between the country of its foundation and the country of its the most frequent investments - United States. Among the most popular portfolio startups of the fund, we may highlight RenaMed Biologics. Moreover, a startup needs to be at the age of 11-15 years to get the investment from the fund. Among the most successful fund investment fields, there are Women's, Biotechnology.
Investments analytics
Analytics
- Total investments
- 3
- Lead investments
- 0
- Exits
- 2
- Investments by industry
- Medical (3)
- Women's (1)
- Manufacturing (1)
- Web Design (1)
- Medical Device (1) Show 2 more
- Investments by region
- United States (2)
- United Kingdom (1)
- Peak activity year
- 2007
Discover reliable insights
Leverage validated data, identify key contacts and secure funding opportunities for your business.Quantitative data
- Avg. startup age at the time of investment
- 23
- Group Appearance index
- 1.00
- Avg. company exit year
- 9
Need more data?
Get access to full data about investors, including their team, contact information, and historic data.
Latest deals
Company name | Deal date | Industry | Deal stage | Deal size | Location |
---|
At Unicorn Nest, we combine cutting-edge technology with human expertise to build one of the most reliable venture capital databases in the market. Our process begins with automated AI-enhanced data collection, leveraging the full potential of Large Language Models (LLMs).
Later, our team of analysts takes it further with manual verification, using proprietary tools for data cleaning and validation to ensure accuracy and reliability. We cross-check and enhance our findings through press and media monitoring, integrating information from trusted news outlets and venture capital aggregators. Finally, we stay ahead of the curve by monitoring social networks like LinkedIn and X.com.